CARNEY LLOYD 4

What Happened
Lloyd Carney, a director of Vertex Pharmaceuticals (VRTX), was reported to have acquired 2,866 shares on May 1, 2026 through an award/grant (derivative acquisition). The filing shows a $0.00 per-share acquisition price and a total reported cash outlay of $0. The filing notes the award is fully vested.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-05 (filed within the standard two business-day window).
• Transaction type: Award/Grant (derivative acquisition) — 2,866 shares at $0.00.
• Footnote: Fully vested.
• Shares owned after transaction: not disclosed in the provided filing.
• No indication this was an open-market purchase or sale (it appears to be a compensation-related award).

Context
This was a compensation-related award vesting (derivative transaction), not a stock purchase on the open market. Such awards are common for directors and reflect compensation rather than a direct buy/sell decision; they should be interpreted differently than open-market purchases or sales.